# US Melanoma Market

> US Melanoma Market Share And Trends Analysis By Type (Superficial Spreading, Nodular, Lentigo Maglina, Acral Lentigious And Others); Gender (Male And Female); Treatment (Immunotherapy, Biologic Therapy, Radiation Therapy, Chemotherapy, Surgery And Others); Diagnosis (Abcde, Ugly Duckling, Biopsy And Others), End Users (Hospitals, Pharmaceutical Companies, Research Centers, Clinics, Laboratories) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.89%
- **2024:** $ 1.57 Billion
- **2025:** $ 1.68 Billion
- **2035:** $ 2.96 Billion
- **Key Players:** Bristol-Myers Squibb (US), Merck & Co. (US), Amgen (US), Genentech (US), Novartis (US), Eli Lilly and Company (US), Pfizer (US), Regeneron Pharmaceuticals (US), Incyte Corporation (US)

**Report ID:** MRFR/Pharma/2164-HCR · **Pages:** 50 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-melanoma-market-2950

---

## Market Summary

## **US Melanoma Market Overview**

The US melanoma market is anticipated to reach USD 5.73 Billion, at a 10.8% CAGR during the forecast period 2022-2032.

Melanoma is a type of cancer that develops from pigment containing cells known as melanocytes. It is the most dangerous type of skin cancer. Sometimes they develop from moles showing significant change in color.

Other changes include an increase in size, itchiness, irregular edges, or skin breakdown. Exposure to ultra violet light in people with low pigment levels is a risk factor. The tumor can be either malignant or benign.

Types of melanoma include superficial spreading melanoma, nodular melanoma, lentigo maglina melanoma, acral lentigious melanoma and others. About 98% of melanoma is localized in the US. Skin cancer is one of the most common cancers in the US.

Treatment options for melanoma include [biologic therapy](../../../reports/biologic-therapy-market-840), immune therapy, radiation therapy, [chemotherapy and surgery](../../../reports/chemotherapy-market-5791). Ultra violet exposure is a known risk factor of melanoma. Superficial spreading melanoma affects a large number of people in the US.

The disease is more common in men than women.

### **US Melanoma Market Segment Insights**

US melanoma market has been segmented on the basis of type including superficial spreading, nodular, lentigo maglina, acral lentigious and others. Segmentation also includes gender male and female.

Treatment segmentation includes immunotherapy, biologic therapy, radiation therapy, chemotherapy, surgery and others. Diagnosis segmentation covers ABCDE, ugly duckling, biopsy, and others. End users include hospitals, pharmaceutical companies, research centers, clinics, and laboratories.

### **Regional Analysis of Melanoma Market**

Melanoma market in the US is divided into states comprising Georgia, New Jersey, North Carolina, New York, Florida, Illinois, Ohio, Pennsylvania, Texas, Washington, California, Virginia and Rest of US.

California accounts for the largest market for melanoma in US followed by Florida and Ohio. California and Florida are key regions for melanoma market. A large number of melanoma cases are found in this region.

New York is the third largest market after Florida. According to American Society of Dermatology, the prevalence of melanoma is gradually increasing, and this spreads across the body. The number of skin cancer patients is growing steadily in Florida and Texas.

This is due to their exposure to ultraviolet rays and extensive use of tanning beds in these regions. Technological advancement in the field of treatment and diagnosis of melanoma in the US also drives this market. The **Food and Drug Administration (FDA)** classifies tanning beds as "moderate risk" devices.

## **Key Players for Melanoma Market**

Some of the Key Players in US melanoma market are:

- Amgen, Inc.
- Bristol-Myers Squibb
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- Janssen Biotech, Inc.
- Novartis International AG
- [**Pfizer**](https://www.pfizer.com/disease-and-conditions/melanoma)
- Vical
- Ziopharm

The report for US melanoma market of Market Research Future comprises extensive primary research along with detailed analysis of qualitative as well as quantitative aspects by various industry experts.

This includes key opinion leaders to gain deeper insight into the market and industry performance. The report gives a clear picture of the current US melanoma market scenario.

This includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the US melanoma market. The report provides detailed information and strategies of the top key players in the industry.

The report also gives a broad study of the different markets segments and regions.

## **Study Objectives of Melanoma Market**

- To provide detailed analysis of the market structure along with forecast for the next six years of various segments and sub-segments of the US melanoma market.
- To provide insights about factors affecting the US melanoma market growth.
- To analyze the melanoma market based on various factors price analysis, supply chain analysis, **Porters Five Force analysis** etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to the US.
- To provide country level analysis of the market with respect to the current US melanoma market size and future prospective.
- To provide country level analysis of the market for segments by type, by end users and its sub-segments.
- To provide overview of key players and their strategic profiling in the US melanoma market, comprehensively analyzing their core competencies, and drawing a **competitive landscape** for the US melanoma market.
- To track and analyze competitive developments such as **joint ventures**, **strategic alliances**, **mergers and acquisitions**, **new product developments**, and **research and developments** in the US melanoma market.

## **Intended Audience**

- Hospitals
- Pharmaceutical companies
- Research and development (R&D) companies
- Academic medical institutes and universities
- Melanoma drug manufactures
- Melanoma drug suppliers

## Market Drivers

### Rising Incidence Rates

The US [Melanoma](https://www.marketresearchfuture.com/reports/melanoma-market-67329) Market is experiencing a notable increase in melanoma incidence rates, with the American Cancer Society estimating that approximately 106,110 new cases of melanoma will be diagnosed in 2026. This rising trend is attributed to factors such as increased sun exposure, tanning bed usage, and genetic predispositions. As awareness of [skin cancer](https://www.marketresearchfuture.com/reports/skin-cancer-market-1173) grows, more individuals are seeking early diagnosis and treatment, thereby driving demand for innovative therapies and screening methods. The growing patient population necessitates advancements in treatment options, which in turn propels the US Melanoma Market forward. Furthermore, the increasing burden on healthcare systems due to rising melanoma cases is likely to stimulate investment in research and development, enhancing the overall market landscape.

### Growing Aging Population

The demographic shift towards an aging population in the United States is significantly impacting the US Melanoma Market. As individuals age, their risk of developing melanoma increases, primarily due to cumulative sun exposure over the years. The US Census Bureau projects that by 2030, nearly 20% of the population will be 65 years or older, leading to a higher prevalence of skin cancers, including melanoma. This demographic trend is likely to result in increased demand for screening, early detection, and treatment options tailored to older adults. Consequently, healthcare providers and pharmaceutical companies are expected to focus on developing age-appropriate therapies and interventions, thereby driving growth in the US Melanoma Market. The intersection of an aging population and rising melanoma incidence presents both challenges and opportunities for market stakeholders.

### Enhanced Diagnostic Technologies

Advancements in diagnostic technologies are transforming the landscape of the US Melanoma Market. The introduction of non-invasive imaging techniques, such as dermoscopy and reflectance confocal microscopy, has improved the accuracy of melanoma detection. These technologies enable healthcare professionals to identify suspicious lesions at an early stage, facilitating timely intervention and treatment. Moreover, the integration of artificial intelligence in diagnostic processes is showing promise in enhancing the precision of melanoma diagnosis. As these technologies become more widely adopted, they are likely to increase the rate of early melanoma detection, which is crucial for improving patient outcomes. The growing emphasis on precision medicine and personalized treatment approaches further underscores the importance of enhanced diagnostic capabilities in the US Melanoma Market.

### Innovative Therapeutic Approaches

The US Melanoma Market is witnessing a surge in innovative therapeutic approaches, particularly in immunotherapy and targeted therapies. Treatments such as checkpoint inhibitors and BRAF/MEK inhibitors have revolutionized melanoma management, leading to improved patient outcomes. The FDA has approved several novel agents, which have contributed to a significant increase in the survival rates of advanced melanoma patients. For instance, the introduction of pembrolizumab and nivolumab has transformed treatment paradigms, making them essential components of melanoma therapy. This innovation not only enhances the quality of care but also drives market growth as healthcare providers and patients increasingly opt for these advanced treatment modalities. The ongoing research and development in this area suggest a promising future for the US Melanoma Market.

### Government Initiatives and Policies

Government initiatives and policies play a crucial role in shaping the US Melanoma Market. The National Cancer Institute and other federal agencies have implemented programs aimed at increasing awareness, funding research, and improving access to melanoma treatments. For example, the Cancer Moonshot initiative seeks to accelerate cancer research and enhance collaboration among stakeholders. Such initiatives are likely to lead to increased funding for melanoma research, which could result in the development of new therapies and diagnostic tools. Additionally, public health campaigns aimed at educating the population about the risks of melanoma and the importance of early detection are expected to further drive market growth. These government efforts create a supportive environment for advancements in the US Melanoma Market.

## Future Outlook

The US Melanoma Market is projected to grow at a 5.89% CAGR from 2025 to 2035, driven by advancements in immunotherapy, increased awareness, and early detection technologies.

**New opportunities:**

- Development of personalized immunotherapy treatments for melanoma patients.
- Expansion of telemedicine platforms for remote patient monitoring and consultations.
- Investment in AI-driven diagnostic tools to enhance early detection rates.

By 2035, the US Melanoma Market is expected to be robust, driven by innovative treatment solutions and enhanced patient engagement.

## Segment Insights

### By Treatment Type: Immunotherapy (Largest) vs. Targeted Therapy (Fastest-Growing)

In the US Melanoma Market, treatment modalities are dynamically evolving with Immunotherapy holding the largest market share. It is increasingly favored due to its ability to enhance the body’s immune response against melanoma cells. Following Immunotherapy are Surgery, Chemotherapy, and Targeted Therapy, which is gaining significant traction. While Surgery remains a conventional approach, the momentum is shifting towards more advanced treatments, with providers advocating for less invasive options that yield better outcomes.

The growth trends within this segment are propelled by advancements in research and clinical trials that favor Immunotherapy options, attributed to their efficacy and tolerability. Moreover, Targeted Therapy is becoming the fastest-growing approach, largely due to its precision in targeting melanoma cells with minimal impact on healthy tissues. As healthcare systems continue to evaluate and adopt personalized treatment strategies, the focus on these therapies is expected to intensify, nudged by rising melanoma incidence rates and heightened awareness about treatment options.

Surgery (Dominant) vs. Chemotherapy (Emerging)

In the current landscape of the US Melanoma Market, Surgery remains the dominant treatment modality recognized for its quick effectiveness in removing tumors. It is often the first-line treatment for melanoma, particularly in early-stage cases, where it proves to be most efficacious. On the other hand, Chemotherapy, once a cornerstone treatment, is transitioning into an emerging role. This shift is largely rooted in the awareness of its limitations and side effects. Chemotherapy's position is now characterized by its use in advanced melanoma stages or when other treatments are not achievable. Despite being less favored compared to newer therapies, it still plays a critical role, particularly in comprehensive treatment regimens, as clinicians seek to optimize outcomes based on patient-specific needs.

### By Stage of Disease: Localized (Largest) vs. Distant (Fastest-Growing)

In the US melanoma market, the stage of disease plays a crucial role in treatment strategies and patient outcomes. Localized melanoma represents the largest portion of the market due to higher early detection rates and effective treatment options available. In contrast, regional and distant stages account for a smaller market share, as they typically involve more complex treatment regimens and poorer prognoses.

Melanoma Stages: Localized (Dominant) vs. Distant (Emerging)

Localized melanoma is characterized by its confinement to the skin, presenting a significantly better prognosis and treatment success due to less aggressive characteristics. This stage is predominantly targeted by preventive measures and early screening programs, which enhance detection rates. Conversely, distant melanoma, which signifies metastasis beyond the initial site, is considered an emerging segment due to its rising incidence and evolving treatment modalities. This segment is witnessing new drug developments and immunotherapies that aim to improve survival rates, driving increased market attention and investment.

### By Patient Demographics: Age (Largest) vs. Gender (Fastest-Growing)

In the US Melanoma Market, the distribution of patient demographics showcases a significant prevalence among older adults, particularly those aged 65 and above, who represent the largest segment. Meanwhile, women have been increasingly diagnosed at a faster rate, indicating a growing awareness and screening practices among this demographic. The underlying statistics suggest that while older adults dominate the patient population, the trend points toward a notable increase in melanoma cases among younger individuals, signifying a shift in demographic patterns.

Moreover, factors contributing to these trends include enhanced education on skin health, increased outdoor exposure, and genetic predispositions that younger individuals are starting to manifest. This trend is compounded by demographic shifts, as younger generations become more engaged in preventive measures and seek early diagnosis. Gender-wise, women’s improved access to dermatologic care and their proactive approach to health screenings play a critical role in their faster growth rate in melanoma cases. This evolving landscape necessitates continuous monitoring to adapt treatment strategies effectively.

Age (Dominant) vs. Gender (Emerging)

The patient demographic for melanoma in the United States highlights age as the dominant factor, especially among those 65 and older, who display the highest incidence rates. This age group is characterized by a lifetime accumulation of sun exposure, combined with a generally weaker immune response, which makes them more susceptible to melanoma. The increase in cases among this demographic is attributed to factors like longer life expectancy and the state of overall skin health, where older skin is more vulnerable to malignancies. On the other hand, the emerging gender demographic indicates an uptick in melanoma diagnoses among women, driven by increasing awareness and better access to healthcare. Gender differences have historically been observed in melanoma presentation, with women often developing the disease at a younger age compared to men. The evolving roles of healthcare campaigns in educating women about skin checks and protective measures against UV exposure have contributed significantly to this shift.

### By Diagnosis Method: Skin Biopsy (Largest) vs. Imaging Tests (Fastest-Growing)

In the US Melanoma Market, the diagnosis method segment is primarily dominated by [Skin Biopsy](https://www.marketresearchfuture.com/reports/skin-biopsy-market-4650), which holds the largest market share. Skin Biopsy serves as the gold standard for definitive melanoma diagnosis, being preferred by clinicians due to its accuracy and reliability. Imaging Tests, while holding a smaller market share, are increasingly being utilized for their non-invasive nature and ability to detect distant metastases, which makes them vital in the staging of melanoma.

Diagnosis Methods: Skin Biopsy (Dominant) vs. Imaging Tests (Emerging)

Skin Biopsy remains the dominant diagnosis method in the US Melanoma Market due to its effectiveness in providing histopathological confirmation of melanoma. This method is favored for its proven reliability and accuracy in identifying malignant cells. In contrast, Imaging Tests are emerging as a significant complementary approach, increasingly adopted for their role in early detection and monitoring treatment responses, particularly with advancements in imaging technology. This trend is driven by patients' preferences for less invasive options, making Imaging Tests the fastest-growing segment within diagnostics. The combined use of these methods enhances early detection rates and improves patient outcomes, marking them as pivotal aspects of melanoma management.

## Competitive Benchmarking

The Melanoma Market in the US is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on personalized medicine. Key players such as Bristol-Myers Squibb (US), Merck & Co. (US), and Amgen (US) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their product offerings. Bristol-Myers Squibb (US) emphasizes immunotherapy advancements, while Merck & Co. (US) focuses on expanding its portfolio through strategic collaborations. Amgen (US) is increasingly investing in targeted therapies, indicating a collective shift towards precision medicine that shapes the competitive environment.

The market structure appears moderately fragmented, with several players vying for market share. Companies are adopting various business tactics, such as localizing manufacturing and optimizing supply chains, to enhance operational efficiency. This competitive structure allows for a diverse range of treatment options, catering to the evolving needs of patients and healthcare providers alike. The influence of key players is significant, as their strategic decisions can impact market dynamics and patient access to innovative therapies.

In December 2025, Merck & Co. (US) announced a collaboration with a leading biotechnology firm to develop a novel combination therapy for advanced melanoma. This strategic move is likely to enhance Merck's competitive edge by broadening its therapeutic offerings and addressing unmet medical needs in the melanoma treatment landscape. The partnership underscores the importance of collaboration in driving innovation and improving patient outcomes.

In November 2025, Bristol-Myers Squibb (US) received FDA approval for a new indication of its leading immunotherapy drug, which is expected to significantly boost its market presence. This approval not only reinforces the company's commitment to advancing melanoma treatment but also positions it favorably against competitors. The strategic importance of this event lies in its potential to attract a larger patient population and enhance revenue streams.

In October 2025, Amgen (US) launched a new targeted therapy specifically designed for patients with a particular genetic mutation associated with melanoma. This launch reflects Amgen's strategic focus on precision medicine and its commitment to addressing the unique needs of melanoma patients. The introduction of this therapy is anticipated to strengthen Amgen's market position and contribute to the ongoing evolution of treatment paradigms in melanoma.

As of January 2026, current trends in the Melanoma Market indicate a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and enhancing the speed of bringing new therapies to market. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technology, and supply chain reliability, as companies strive to meet the growing demand for effective and personalized melanoma treatments.

## Report Scope

| MARKET SIZE 2024 | 1.57(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.68(USD Billion) |
| MARKET SIZE 2035 | 2.96(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.89% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol-Myers Squibb (US), Merck & Co. (US), Amgen (US), Genentech (US), Novartis (US), Eli Lilly and Company (US), Pfizer (US), Regeneron Pharmaceuticals (US), Incyte Corporation (US) |
| Segments Covered | Treatment Type, Stage of Disease, Patient Demographics, Diagnosis Method |
| Key Market Opportunities | Advancements in targeted therapies and immunotherapies enhance treatment options in the US Melanoma Market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the US Melanoma Market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US Melanoma Market as of 2024?**
A: The US Melanoma Market was valued at 1.57 USD Billion in 2024.

**Q: What is the projected market valuation for the US Melanoma Market in 2035?**
A: The market is projected to reach 2.96 USD Billion by 2035.

**Q: What is the expected CAGR for the US Melanoma Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US Melanoma Market during 2025 - 2035 is 5.89%.

**Q: Which treatment type segment had the highest valuation in 2024?**
A: In 2024, the Immunotherapy segment had the highest valuation at 0.63 USD Billion.

**Q: How does the Localized stage of disease segment perform in terms of valuation?**
A: The Localized stage of disease segment was valued at 0.79 USD Billion in 2024 and is expected to grow significantly.

**Q: What are the projected valuations for the Surgery treatment type segment by 2035?**
A: The Surgery treatment type segment is projected to reach between 0.47 and 0.88 USD Billion by 2035.

**Q: Which demographic factors are influencing the US Melanoma Market?**
A: Factors such as Age, Gender, Ethnicity, and Socioeconomic Status are influencing the market, with valuations ranging from 0.3 to 0.95 USD Billion in 2024.

**Q: What diagnostic methods are utilized in the US Melanoma Market?**
A: Diagnostic methods include Skin Biopsy, Imaging Tests, and Dermatoscopy, with valuations of 0.7, 0.5, and 0.37 USD Billion respectively in 2024.

**Q: Who are the key players in the US Melanoma Market?**
A: Key players include Bristol-Myers Squibb, Merck & Co., Amgen, Genentech, Novartis, Eli Lilly and Company, Pfizer, Regeneron Pharmaceuticals, and Incyte Corporation.

**Q: What is the expected growth trend for the Regional stage of disease segment by 2035?**
A: The Regional stage of disease segment is projected to grow from 0.56 USD Billion in 2024 to between 1.06 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-melanoma-market-2950*